GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (STU:C6K0) » Definitions » Beginning Cash Position

Avalo Therapeutics (STU:C6K0) Beginning Cash Position : €124.59 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Avalo Therapeutics Beginning Cash Position?

Avalo Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2025 was €124.59 Mil.

Avalo Therapeutics's quarterly Beginning Cash Position declined from Sep. 2024 (€84.30 Mil) to Dec. 2024 (€78.34 Mil) but then increased from Dec. 2024 (€78.34 Mil) to Mar. 2025 (€124.59 Mil).

Avalo Therapeutics's annual Beginning Cash Position declined from Dec. 2022 (€51.79 Mil) to Dec. 2023 (€12.21 Mil) and declined from Dec. 2023 (€12.21 Mil) to Dec. 2024 (€7.21 Mil).


Avalo Therapeutics Beginning Cash Position Historical Data

The historical data trend for Avalo Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Beginning Cash Position Chart

Avalo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.07 16.91 51.79 12.21 7.21

Avalo Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.94 102.48 84.30 78.34 124.59

Avalo Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Avalo Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalo Therapeutics Business Description

Traded in Other Exchanges
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics Headlines

No Headlines